[go: up one dir, main page]

CY2019045I2 - Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου - Google Patents

Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου

Info

Publication number
CY2019045I2
CY2019045I2 CY2019045C CY2019045C CY2019045I2 CY 2019045 I2 CY2019045 I2 CY 2019045I2 CY 2019045 C CY2019045 C CY 2019045C CY 2019045 C CY2019045 C CY 2019045C CY 2019045 I2 CY2019045 I2 CY 2019045I2
Authority
CY
Cyprus
Prior art keywords
salt
acylaminothiazole derivative
acylaminothiazole
derivative
Prior art date
Application number
CY2019045C
Other languages
English (en)
Other versions
CY2019045I1 (el
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY2019045I2 publication Critical patent/CY2019045I2/el
Publication of CY2019045I1 publication Critical patent/CY2019045I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CY2019045C 2002-01-18 2019-12-17 Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου CY2019045I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002010447 2002-01-18
JP2002010413 2002-01-18
PCT/JP2003/000270 WO2003062233A1 (en) 2002-01-18 2003-01-15 2-acylaminothiazole derivative or salt thereof

Publications (2)

Publication Number Publication Date
CY2019045I2 true CY2019045I2 (el) 2020-05-29
CY2019045I1 CY2019045I1 (el) 2020-05-29

Family

ID=27615666

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100629T CY1114169T1 (el) 2002-01-18 2013-07-24 Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου
CY2019045C CY2019045I1 (el) 2002-01-18 2019-12-17 Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100629T CY1114169T1 (el) 2002-01-18 2013-07-24 Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου

Country Status (17)

Country Link
US (4) US7638536B2 (el)
EP (2) EP2314586B1 (el)
JP (2) JP4120586B2 (el)
KR (1) KR101010905B1 (el)
CN (1) CN1319967C (el)
BE (1) BE2019C547I2 (el)
CA (1) CA2472711C (el)
CY (2) CY1114169T1 (el)
DK (1) DK1466912T3 (el)
ES (2) ES2416304T3 (el)
FR (1) FR19C1072I2 (el)
HU (1) HUS1900052I1 (el)
LU (1) LUC00137I2 (el)
NL (1) NL301020I2 (el)
PT (1) PT1466912E (el)
SI (1) SI1466912T1 (el)
WO (1) WO2003062233A1 (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
SI1466912T1 (sl) 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
AU2003218736B2 (en) * 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
EP1647553A4 (en) 2003-07-17 2008-12-31 Astellas Pharma Inc 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF
CA2535511C (en) * 2003-08-12 2009-11-17 Shionogi And Co., Ltd. Compounds having thrombopoietin receptor agonism
CN1902196B (zh) * 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
AU2004321997A1 (en) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
AR051095A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
NZ554662A (en) * 2004-10-25 2008-11-28 Ligand Pharm Inc Thrombopoietin activity modulating compounds and methods
MX2007006819A (es) * 2004-12-08 2007-07-24 Nissan Chemical Ind Ltd Compuestos heterociclicos sustituidos con 3-etilidenohidrazino como activadores del receptor de trombopoyetina.
EP1845090A4 (en) 2004-12-14 2009-11-11 Nissan Chemical Ind Ltd AMIDE COMPOUND AND THROMBOPOIETINE RECEPTOR ACTIVATOR
JP4774995B2 (ja) * 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
JP4665769B2 (ja) * 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
WO2007004038A1 (en) * 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2007036769A1 (en) * 2005-07-05 2007-04-05 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
MX2008000470A (es) * 2005-07-13 2008-03-11 Astrazeneca Ab Analogos de piridina nuevos.
CA2609319C (en) 2005-07-15 2014-02-04 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
TWI330184B (en) 2005-07-20 2010-09-11 Nissan Chemical Ind Ltd Pyrazole compounds and thrombopoietin receptor activators
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
WO2007054783A2 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
WO2008021283A2 (en) * 2006-08-08 2008-02-21 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans
JP5164510B2 (ja) * 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
CA2694567C (en) 2007-07-31 2013-04-23 Shionogi & Co., Ltd. Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
EP2211855A4 (en) * 2007-10-09 2011-12-07 Univ Pennsylvania THROMBOPOETIN RECEPTOR AGONIST (TPORA) DESTRUCTS ACUTE MYELOUS LEUKEMIA CELLS IN HUMANS
ES2581386T3 (es) * 2008-02-25 2016-09-05 Merck Patent Gmbh Activadores de la glucoquinasa
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
JP2013501811A (ja) * 2009-08-14 2013-01-17 エーザイ インコーポレーテッド 血小板産生を刺激するためのｅ５５０１の使用
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) * 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JP2014144916A (ja) 2011-08-03 2014-08-14 Astellas Pharma Inc ２−アシルアミノチアゾール化合物の結晶
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013073577A1 (ja) 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
SG11201504704TA (en) 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
ES2633987T3 (es) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK
WO2015186821A1 (ja) 2014-06-06 2015-12-10 アステラス製薬株式会社 ２－アシルアミノチアゾール誘導体またはその塩
CN106573928B (zh) * 2014-08-26 2020-04-14 安斯泰来制药株式会社 2-氨基噻唑衍生物或其盐
SG11201703407UA (en) 2014-10-31 2017-05-30 Nissan Chemical Ind Ltd Ligand-binding fiber and cell culture substrate using said fiber
JP2019529342A (ja) * 2016-09-08 2019-10-17 四川科倫博泰生物医薬股▲フン▼有限公司Ｓｉｃｈｕａｎ Ｋｅｌｕｎ−Ｂｉｏｔｅｃｈ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 新型２−アミドチアゾール誘導体、及びその製造方法と用途
CN106749226B (zh) * 2017-03-15 2019-12-20 广东赛拓医药科技有限公司 一种avatrombopag马来酸盐晶型C的制备方法
CN107383000A (zh) * 2017-08-07 2017-11-24 瑞阳制药有限公司 血小板增多剂的制备方法
WO2020044364A1 (en) 2018-08-27 2020-03-05 Mylan Laboratories Limited Polymorphic forms of avatrombopag maleate
RU2709496C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения аватромбопага
CN110586047B (zh) * 2019-10-08 2022-03-11 辽宁工业大学 一种用于吸附铅离子的改性双醛淀粉制备方法
CN111620863A (zh) * 2020-06-23 2020-09-04 苏州明锐医药科技有限公司 阿曲波帕的制备方法
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法
CN115477645A (zh) * 2022-09-28 2022-12-16 湖南先施制药有限公司 马来酸阿伐曲泊帕系列杂质及其制备方法和应用
CN116813609A (zh) * 2023-07-03 2023-09-29 上海天鹤年药业有限公司 一种阿伐曲泊帕的制备方法
WO2025132929A2 (en) 2023-12-19 2025-06-26 Synthon B.V Salts of avatrombopag
WO2025133011A1 (en) 2023-12-21 2025-06-26 Synthon B.V Formulation comprising form b of avatrombopag maleate
EP4660195A1 (en) 2024-06-05 2025-12-10 Noucor Health S.A. Crystalline forms of avatrombopag maleate and preparation thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
TW205041B (el) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
US5256675A (en) 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
JPH078863B2 (ja) 1989-09-21 1995-02-01 久光製薬株式会社 新規なジフェニルチアゾール誘導体
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
JPH03199451A (ja) 1989-12-26 1991-08-30 Asahi Chem Ind Co Ltd エアージェットルーム用筬
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
JP3173876B2 (ja) 1992-06-26 2001-06-04 日本パイオニクス株式会社 有害ガスの検知システム
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
EP0768311B1 (en) * 1995-03-09 2003-08-06 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazole derivatives
AU700837B2 (en) 1995-04-28 1999-01-14 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
PL188795B1 (pl) * 1995-06-07 2005-04-29 Glaxo Group Ltd Związek wiążący się z receptorem trombopoetyny, kompozycja farmaceutyczna i zastosowanie związku wiążącego się z receptorem trombopoetyny
US5963666A (en) * 1995-08-18 1999-10-05 International Business Machines Corporation Confusion matrix mediated word prediction
US6040335A (en) * 1995-10-17 2000-03-21 Suntory Limited Therapeutics for thrombocytopenia
EP0920314B1 (en) 1996-05-22 2003-08-27 Smithkline Beecham Corporation Non-peptide g-csf mimetics
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
JPH10212289A (ja) 1997-01-31 1998-08-11 Kyowa Hakko Kogyo Co Ltd ピロロフェナンスリジン誘導体
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
JPH11152276A (ja) 1997-11-20 1999-06-08 Hokuriku Seiyaku Co Ltd ベンゾジアゼピン誘導体
JP2000044562A (ja) 1998-07-31 2000-02-15 Kyowa Hakko Kogyo Co Ltd ピロロフタルイミド誘導体
EP1114039A1 (en) 1998-09-18 2001-07-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
US6498155B1 (en) * 1998-11-17 2002-12-24 Smithkline Beecham Corporation Methods of treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1844766B1 (en) 2000-12-18 2012-04-18 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
EP1357116A4 (en) * 2001-02-02 2005-06-01 Yamanouchi Pharma Co Ltd 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
SI1466912T1 (sl) 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2003084544A2 (en) 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
TWI280127B (en) 2002-06-11 2007-05-01 Inst Med Molecular Design Inc Remedies for neurodegenerative diseases
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
WO2004029049A1 (ja) 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
CA2514363A1 (en) 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
EP1610793A2 (en) * 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
EP1647553A4 (en) * 2003-07-17 2008-12-31 Astellas Pharma Inc 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF
CA2535511C (en) 2003-08-12 2009-11-17 Shionogi And Co., Ltd. Compounds having thrombopoietin receptor agonism
WO2007054783A2 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
WO2008021283A2 (en) * 2006-08-08 2008-02-21 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans

Also Published As

Publication number Publication date
CY1114169T1 (el) 2016-08-31
SI1466912T1 (sl) 2013-08-30
FR19C1072I2 (fr) 2021-03-26
NL301020I2 (nl) 2020-04-21
DK1466912T3 (da) 2013-07-01
LUC00137I1 (el) 2019-11-14
KR20040078122A (ko) 2004-09-08
US20050153977A1 (en) 2005-07-14
HUS1900052I1 (hu) 2020-01-28
JPWO2003062233A1 (ja) 2005-05-19
WO2003062233A1 (en) 2003-07-31
US8338429B2 (en) 2012-12-25
EP1466912A1 (en) 2004-10-13
PT1466912E (pt) 2013-06-28
LUC00137I2 (el) 2020-06-12
CA2472711A1 (en) 2003-07-31
CN1639157A (zh) 2005-07-13
FR19C1072I1 (fr) 2020-01-17
US7638536B2 (en) 2009-12-29
NL301020I1 (el) 2019-12-16
BE2019C547I2 (el) 2022-05-17
JP4844574B2 (ja) 2011-12-28
ES2416304T3 (es) 2013-07-31
JP2008111001A (ja) 2008-05-15
JP4120586B2 (ja) 2008-07-16
US20100222329A1 (en) 2010-09-02
EP1466912A4 (en) 2006-01-11
EP2314586A1 (en) 2011-04-27
CY2019045I1 (el) 2020-05-29
CN1319967C (zh) 2007-06-06
EP1466912B1 (en) 2013-04-24
EP2314586B1 (en) 2016-09-14
KR101010905B1 (ko) 2011-01-25
US8765764B2 (en) 2014-07-01
US20100222361A1 (en) 2010-09-02
US20130079351A1 (en) 2013-03-28
ES2610611T3 (es) 2017-04-28
CA2472711C (en) 2012-03-20

Similar Documents

Publication Publication Date Title
CY2019045I2 (el) Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου
NO2021052I1 (no) relugolix or a salt thereof
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE420066T1 (de) Amidoacetonitrilderivate
ATE352550T1 (de) Chinazolinderivate
EP1557594A4 (en) OIL RING
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS2656B (is) Nýjar besímídasólafleiður
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DK1633719T3 (da) Substituerede spirobenzazepiner
DE502004009935D1 (de) Substituierte dihydrochinazoline ii
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls